Older Americans bore the brunt of antibiotic-resistant infections, study finds
Older Americans were disproportionately affected by several different types of infection for which antibiotics were largely ineffective, resulting in nearly 12,000 deaths and costing the U.S. health care system almost $1.9 billion in 2017, a new study found.
Of those deaths, 40% were estimated to have occurred among those 65 years and older, while this...
U.S. Hospitals Lose Legal Challenge to Trump Price Transparency Rule
Regeneron Funneled Kickbacks Through a Patient Charity, Federal Lawsuit Claims
The drugmaker Regeneron funneled tens of millions of dollars to a charity that paid the out-of-pocket costs for patients who took the company’s expensive eye drug, then lied to internal auditors about it, according to a lawsuit filed Wednesday by federal prosecutors in Massachusetts.
The suit, filed in the U.S. District Court of Massachusetts in...
Drug firms offer to settle U.S. opioid suits with $50 billion package: sources
Five drugmakers and distributors are offering $22 billion in cash as well as drugs and services they value at $28 billion to resolve lawsuits alleging the industry fueled the U.S. opioid crisis, two sources familiar with the matter said on Wednesday.
The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals...
Celgene settles antitrust lawsuit over cancer drugs for $55 million
Celgene Corp has agreed to pay $55 million to resolve claims that the drugmaker engaged in an multi-faceted scheme to maintain a monopoly over the market for its cancer treatment drugs Thalomid and Revlimid and delay generic competition.
The settlement was disclosed in a filing on Wednesday in federal court in Newark, New Jersey, and...
U.S. group says Novartis MS drug price out of line with benefit
A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple sclerosis drug Mayzent, calling its $88,561 list price “far out of line” compared with its benefits for patients.
Read More
Drugmakers fight rule to disclose prices in TV ads
A bid by the Trump administration to shine light on the high costs of prescription drugs prompted legal resistance Friday by three major pharmaceutical companies.
Amgen, Eli Lilly, and Merck sued the Department of Health and Human Services in a bid to block new rules requiring that companies disclose the “list price’’ of their drugs...
Heart-Drug Suppliers for Millions Faulted Over Data, Bugs, Dirt
A pair of drugmakers in India that the U.S. is counting on to produce generic blood-pressure pills after a far-reaching recall have been faulted by regulators for quality-control issues.
Read More
The Death of Antibiotics: We’re Running Out of Effective Drugs to Fight Off an Army of Superbugs
In January, Columbia University revealed that four patients at its Irving Medical Center in New York had been sick with an unusual version of E. coli , a common gut bacterium. Although the news largely escaped attention in the media, it ricocheted through the world of infectious disease experts. E. coli is a relatively...
States: Drugmakers collude on generic price hikes, overcharge consumers and states billions
A coalition of attorneys general from 43 states and Puerto Rico claim in a federal lawsuit that generic drug manufacturers conspired to fix prices and markets of 114 drugs for both minor infections and chronic diseases such as arthritis, cancer, diabetes and HIV.
Read More